Breukink Myrte B, Mohabati Danial, van Dijk Elon H C, den Hollander Anneke I, de Jong Eiko K, Dijkman Greet, Keunen Jan E E, Hoyng Carel B, Boon Camiel J F
Department of Ophthalmology, Radboud University Medical Center, Nijmegen, the Netherlands.
Department of Ophthalmology, Leiden University Medical Center, Leiden, the Netherlands.
Acta Ophthalmol. 2016 Sep;94(6):565-72. doi: 10.1111/aos.13059. Epub 2016 May 6.
To investigate whether patients who developed chronic central serous chorioretinopathy (cCSC) in association with corticosteroid treatment respond differently to photodynamic therapy (PDT) as compared to patients who have not used corticosteroids.
Clinical evaluation included visual acuity (VA), fundoscopy, optical coherence tomography (OCT), fluorescein and indocyanine green angiography. The main outcome measure was a complete resolution of subretinal fluid (SRF) on OCT after PDT.
One hundred and twenty-three eyes (117 patients), including 35 steroid-associated cases (29%), who received PDT treatment with reduced settings for active cCSC were included. Complete resolution of SRF on OCT was seen in 69% of the steroid-associated cases and in 50% of the controls after PDT treatment (p = 0.062). At the final follow-up moment, 74% of the cases had a complete resolution of SRF compared to 60% in the control group (p = 0.142). The VA at the first visit after therapy showed an increase in both groups (mean VA before treatment; cases: 69 ± 14 Early Treatment Diabetic Retinopathy Study (ETDRS) letters, controls: 74 ± 13 ETDRS letters, mean VA first visit after treatment; cases: 76 ± 13 ETDRS letters, controls: 75 ± 13 ETDRS letters). No significant differences were seen in response to PDT between the patients who continued corticosteroid treatment and those who ceased the use of corticosteroids.
Photodynamic therapy appears to be equally effective in patients suffering from steroid-associated cCSC as compared to patients with cCSC who do not use corticosteroids. Continuation of corticosteroids at the time of PDT treatment does not seem to adversely affect PDT response.
研究与皮质类固醇治疗相关的慢性中心性浆液性脉络膜视网膜病变(cCSC)患者与未使用皮质类固醇的患者相比,对光动力疗法(PDT)的反应是否不同。
临床评估包括视力(VA)、眼底检查、光学相干断层扫描(OCT)、荧光素和吲哚菁绿血管造影。主要结局指标是PDT后OCT上视网膜下液(SRF)完全消退。
纳入123只眼(117例患者),其中35例(29%)为类固醇相关病例,接受了针对活动性cCSC的低剂量PDT治疗。PDT治疗后,69%的类固醇相关病例和50%的对照组在OCT上SRF完全消退(p = 0.062)。在最后随访时,74%的病例SRF完全消退,而对照组为60%(p = 0.142)。治疗后首次就诊时两组的视力均有所提高(治疗前平均视力;病例组:69 ± 14糖尿病视网膜病变早期治疗研究(ETDRS)视力表字母,对照组:74 ± 13 ETDRS视力表字母,治疗后首次就诊时平均视力;病例组:76 ± 13 ETDRS视力表字母,对照组:75 ± 13 ETDRS视力表字母)。继续使用皮质类固醇治疗的患者与停止使用皮质类固醇的患者对PDT的反应无显著差异。
与未使用皮质类固醇的cCSC患者相比,光动力疗法对类固醇相关cCSC患者似乎同样有效。PDT治疗时继续使用皮质类固醇似乎不会对PDT反应产生不利影响。